DDInter1570 DDInter832
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism.
Ranolazine {u} (Compound) resembles {v} (Compound) Guaifenesin
Ranolazine {u} (Compound) resembles {v} (Compound) Bupivacaine
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
Ranolazine {u} (Compound) upregulates {v} (Gene) DENND2D
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Ranolazine {u} (Compound) downregulates {v} (Gene) ATP6V1D
Ranolazine {u} (Compound) causes {v} (Side Effect) Underweight
Ranolazine (Compound) resembles Guaifenesin (Compound)
Ranolazine (Compound) resembles Bupivacaine (Compound)
Ranolazine (Compound) binds CYP2D6 (Gene)
Ranolazine (Compound) upregulates DENND2D (Gene)
Ranolazine (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Ranolazine (Compound) downregulates ATP6V1D (Gene)
Ranolazine (Compound) causes Underweight (Side Effect)